What Is the Significance of Variant Histology in Urothelial Carcinoma?
Niyati Lobo(Frimley Health NHS Foundation Trust), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Mario I. Fernández(Clínica Alemana), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Wassim Kassouf(McGill University), John A. Taylor(UConn Health), Stephen B. Williams(Cedars-Sinai Medical Center), Morgan Rouprêt(Sorbonne Université), Jianjun Gao(Chinese General Hospital College of Nursing and Liberal Arts), Shahrokh F. Shariat(Universitätszahnklinik Wien), Ananya Choudhury(University of Manchester), Charles C. Guo(The University of Texas MD Anderson Cancer Center)
Cited by 251
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k